Brief: Lucid Diagnostics Announces Positive Data From Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study
02/07/2024 13:32
July 2 (Reuters) - Lucid Diagnostics Inc LUCD.O :
* LUCID DIAGNOSTICS ANNOUNCES POSITIVE DATA FROM ITS
ESOGUARD BE-1
PROSPECTIVE, INTERNATIONAL, MULTICENTER CLINICAL VALIDATION
STUDY OF ESOGUARD® ESOPHAGEAL PRECANCER TESTING IN A SCREENING
POPULATION
Source text for Eikon: ID:nPn3vCXL3a
Further company coverage: LUCD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PAVmed
See all newsBrief: Lucid Diagnostics Begins Receiving Medicare Reimbursement For Esoguard® And Closes $15 Million Financing
PAVmed Inc reports results for the quarter ended June 30 - Earnings Summary
PAVmed Inc expected to post a loss of 47 cents a share - Earnings Preview
NASDAQ RESUMED AT 11:36 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:21 AM